Evidence map›Paper›PMID 36291029›Full record

ArticleBiosensors2022

Detection of SARS-CoV-2 Neutralizing Antibodies in Vaccinated Pregnant Women and Neonates by Using a Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader.

Wei-Chun Chen, Yen-Pin Lin, Chao-Min Cheng, Ching-Fen Shen, Chang-Wei Li, Yu-Kuo Wang, Ting-Ying Shih, Chitsung Hong, Ting-Chang Chang, Ching-Ju Shen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wei-Chun ChenInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan.ORCID 0000-0002-6515-0996
Yen-Pin LinInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan.
Chao-Min ChengInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan.ORCID 0000-0002-8644-1960
Ching-Fen ShenDepartment of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0001-5926-0462
Chang-Wei LiAllBio Life Inc., Taichung 408, Taiwan.
Yu-Kuo WangAllBio Life Inc., Taichung 408, Taiwan.
Ting-Ying ShihAllBio Life Inc., Taichung 408, Taiwan.
Chitsung HongSpectrochip Inc., Hsinchu 302, Taiwan.ORCID 0000-0002-4983-1046
Ting-Chang ChangDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
Ching-Ju ShenDepartment of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan.ORCID 0000-0002-9975-4210
Chang Gung University · TWKaohsiung Medical University · TWNational Tsing Hua University · TWPowerchip (Taiwan) · TW

Funding

Chang Gung Memorial Hospital CMRPG2L0261Chang Gung Memorial Hospital CMRPGVM0011Chang Gung Memorial Hospital CORPG3J0441Chang Gung Memorial Hospital CRRPG2L0011Ministry of Science and Technology 109-2222-E-182A-002National Tsing Hua University 110F7MAIE1National Tsing Hua University 110F7MBME1
6 · The paper itself

Abstract

The focus of this study was to investigate the detection of neutralizing antibodies (Nabs) in maternal serum and cord blood as the targeted samples by employing a lateral flow immunoassay combined with a spectrum reader (LFI-SR) and the correlation of Nab protection against different types of SARS-CoV-2. We enrolled 20 pregnant women who were vaccinated with the Moderna (mRNA-1273) vaccine during pregnancy and collected 40 samples during delivery. We used an LFI-SR for the level of spike protein receptor binding domain antibody (SRBD IgG) as Nabs and examined the correlation of the SRBD IgG concentration and Nab inhibition rates (NabIR) via enzyme-linked immunosorbent assays (ELISA). The LFI-SR had high confidence for the SRBD IgG level (p < 0.0001). Better NabIR were found in wild-type SARS-CoV-2 (WT) compared to Delta-type (DT) and Omicron-type (OT). Women with two-dose vaccinations demonstrated greater NabIR than those with a single dose. The cut-off value of the SRBD IgG level by the LFI-SR for NabIR to DT (≥30%; ≥70%) was 60.15 and 150.21 ng/mL for mothers (both p = 0.005), and 156.31 (p = 0.011) and 230.20 ng/mL (p = 0.006) for babies, respectively. An additional vaccine booster may be considered for those mothers with SRBD IgG levels < 60.15 ng/mL, and close protection should be given for those neonates with SRBD IgG levels < 150.21 ng/mL, since there is no available vaccine for them.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralFemaleHumansImmunoassayImmunoglobulin GInfant, NewbornPregnancyPregnant PeopleSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GSpike Glycoprotein, CoronavirusCOVID-19 vaccineDelta-type SARS-CoV-2lateral flow immunoassayneutralizing antibodiesOmicron-type SARS-CoV-2S1RBD IgGwild-type SARS-CoV-2

Identifiers

PMID36291029
PMCPMC9599695
OpenAlexW4306737470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.